SorAfenib Versus RADIOEMBOLIZATION in Advanced Hepatocellular Carcinoma
Status:
Completed
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether RADIOEMBOLIZATION with 90 Yttrium
microspheres is more effective on overall survival in advanced Hepatocellular carcinoma (HCC)
with or without portal venous obstruction and no extrahepatic extension than sorafenib which
is now the standard treatment of advanced HCC.